Search Results for: weekly reads

Weekly reads: upbeat stem cell clinical trials update, CRISPR ups & downs, story of 1st marrow transplant survivor

stem cell clinical trials

It’s always great to read about stem cell clinical trials that are looking encouraging. Stem cell clinical trials Proving a new therapy is safe and effective is so challenging. Remarkably, there are more than 9,300 stem cell clinical trials listed for a “stem cell” search on Clinicaltrials.gov. Of course, not all of these are actual […]

Weekly reads: upbeat stem cell clinical trials update, CRISPR ups & downs, story of 1st marrow transplant survivor Read More »

Weekly reads: stem cell activator, sleep & stem cells, clonal hematopoiesis

stem cells macrophages, stem cell activator

When people find out that I’m a stem cell researcher, a common question is whether there’s something they can take that is a stem cell activator. I’ve written before about whether there are stem cell boosts that one can do to try to be healthier. Sleep, stem cell activator and clonality Mostly when I bring

Weekly reads: stem cell activator, sleep & stem cells, clonal hematopoiesis Read More »

Weekly reads: CRISPR, FDA stem cell loss, pioneering AMD study, MS, Verve Therapeutics

FDA stem cell policy flow chart.

The big news of the week was the big FDA stem cell in court by Judge Jesus Bernal here in California, who ruled in favor of a chain of stem cell clinics called Cell Surgical Network. The FDA had been seeking an injunction against the clinics. I believe the ruling was founded in part on

Weekly reads: CRISPR, FDA stem cell loss, pioneering AMD study, MS, Verve Therapeutics Read More »

Weekly reads: taste buds, organoids, good news on CRISPR safety

Taste buds diagram

As I’ve mentioned recently, it’s my busy time for medical school teaching and not long ago we did a GI lab that included one of my favorite structures in the course: taste buds. Taste buds The medical students seem fascinated with taste buds too. I can tell as their professor when something is particularly interesting

Weekly reads: taste buds, organoids, good news on CRISPR safety Read More »

Weekly reads: fibroblasts, gene-editing, Mitalipov, personhood, embryos

NIH 3T3 fibroblasts ATCC

I have a soft spot for fibroblasts, perhaps because one of the first immortalized cell lines I ever grew was NIH3T3. These are mouse fibroblasts that have been immortalized. They are very useful for a variety of experiments. I used them to study an oncogene called E2A-PBX1. Experience with fibroblasts including 3T3s I was amazed

Weekly reads: fibroblasts, gene-editing, Mitalipov, personhood, embryos Read More »

Weekly reads: freeze-dried cloning, FDA signals, stem cell escapees

Human-cloning

Cloning is one of those topics that both fascinates and kind of scares people, especially the idea of duplicating people. I regularly cover the topic here on The Niche because stem cell technologies are involved. Also, one form of the process sometimes called “therapeutic cloning” involves embryonic stem cells. Duplicating mammals has now long been

Weekly reads: freeze-dried cloning, FDA signals, stem cell escapees Read More »

Weekly reads: NIH grants, side effect of darker hair, FDA warning, CRISPR

Grant writers handbook, grants cartoon

The last six months I’ve been spending even more time than usual writing NIH grants (and a few others). The last two weeks have been especially busy on this front as I am getting an R01 renewal out the door. My paper reading lately has been mostly related to the grant writing I’m doing. Still,

Weekly reads: NIH grants, side effect of darker hair, FDA warning, CRISPR Read More »

Weekly reads: teratoma in iPSC trial, Piero Anversa & friends, Athersys, China Initiative

Dr-Piero-Anversa

It’s been mostly a downbeat week on the stem cell news front including a deep revisit by Reuters to the Piero Anversa case that has new revelations. It’s ugly stuff involving other folks too. We’ll start on the iPS cell front, where a trial participant had a teratoma. I’ve had a long-standing interest in the

Weekly reads: teratoma in iPSC trial, Piero Anversa & friends, Athersys, China Initiative Read More »

Weekly reads: Jan Nolta recognition, new director after Irv, FDA guidance

Dr. Jan Nolta UC Davis

People are the real driving force in the stem cell and regenerative medicine field including my colleague Jan Nolta here at UC Davis. She is the Director of our Stem Cell Program. There’s also news about Stanford’s stem cell Director Irv Weissman. Jan Nolta receives award Jan’s lab is prolific and in many ways is

Weekly reads: Jan Nolta recognition, new director after Irv, FDA guidance Read More »